背景:早在1942年，鍶-89就展現出其在攝護腺癌轉移病怠身上之骨痛舒緩效果。本實驗進行銘之生物體分佈實艙。唯鍵-89僅釋放p粒子，較不適合進行動物體分佈實驗。我們使用核能研究所配製之錯-85-氣化鈍，藉以評估鈍-89-氣化站在動物體內之分佈情形。

方法:將0.4mCi鍶-85-氯化鍶製劑靜脈注入鼠體，並分 別於1小時、4小時、24小時、48小時和72小時，摘取內臟色括肺、肝、腎、牌、辛九、肌肉、和骨骼，分別測定其放射活性濃度。另外，取出1m1的血來作測試。組 織放射活性濃度以每g或每ml所含注射藥物之百分比來表示(%ID/g或ml)。

結果:初步結果顯示鍶，的明顯積聚於骨絡組織，在注射後第一小時鍶-85積於骨骼系統積聚的濃度達3.23%ID旬， 至72小時時鍶-85積聚於骨骼系統之濃度高達4.94%ID/g。

結論:本研究顯示核研所鍶-85-氯化鍶製劑能有效的聚集於骨骼系統，據以推估鍶-89-氯化鍶應有相同之結果。

Background: As early as 1942，的Sr was shown to be effective for treatment of pain in patients with metastatic prostate cancer. In this study， we analyzed the biodistribution of strontium in rats. However， 89Sr only emits f3particles which are not suitable for a biodistribution study. Therefore， in this study， we used 85Sr instead of 89Sr to assess the distribution of strontium after intravenous injection in rats.

Methods: After being injected with approximately 14.8 MBq (0.4 mCi)85Sr which was produced by the Institute of Nuclear Energy Research (INER) in a volume of 0.1 ml intravenously， the rats were killed at 1 hr， 4 hrs， 24 hrs， 48 hrs and 72 hrs. Samples (about 0.1 g) of lung， liver， kidney， spleen， testis， muscle， and bone were taken and weighed carefully. In addition， a 1-ml sample of blood was drawn from the heart immediately after killing. Tissue concentrations were calculated and expressed as percent injected dose per gram or per ml (% injected doselg or ml).

Results: Our results showed showed that 85Sraccumulated obviously in the skeletal system. The accumulation reached 3.23% ID/g at the first hour after injection of 85Sr. The accumulation was as high as 4.94% ID/g within 72 hours after injection of 85Sr.

Conclusion: Our study demonstrated that 85Sr-SrCI2could effectively accumulate in the skeletal system. Same can be expected for 89Sr-SrCI2.